Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1950 1
1951 2
1952 4
1953 18
1954 17
1955 11
1956 13
1957 12
1958 16
1959 5
1963 2
1964 3
1965 32
1966 80
1967 106
1968 113
1969 128
1970 149
1971 121
1972 160
1973 202
1974 223
1975 257
1976 170
1977 171
1978 184
1979 219
1980 202
1981 185
1982 211
1983 258
1984 255
1985 256
1986 244
1987 250
1988 318
1989 254
1990 283
1991 348
1992 395
1993 413
1994 475
1995 475
1996 469
1997 503
1998 532
1999 622
2000 671
2001 655
2002 734
2003 798
2004 878
2005 889
2006 967
2007 1024
2008 1066
2009 1093
2010 1039
2011 1143
2012 1206
2013 1369
2014 1279
2015 1319
2016 1381
2017 1425
2018 1452
2019 1475
2020 1604
2021 1542
2022 1351
2023 1280
2024 421

Text availability

Article attribute

Article type

Publication date

Search Results

34,081 results

Results by year

Filters applied: . Clear all
Page 1
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials.
Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, Salgado RD, Klein P. Pong AW, et al. Expert Opin Emerg Drugs. 2022 Mar;27(1):75-90. doi: 10.1080/14728214.2022.2059464. Epub 2022 Apr 1. Expert Opin Emerg Drugs. 2022. PMID: 35341431
INTRODUCTION: Despite the existence of over 30 anti-seizure medications (ASM), including 20 over the last 30 years, a third of patients with epilepsy remain refractory to treatment, with no disease-modifying or preventive therapies until very recently. ...AREAS COVERED: AS …
INTRODUCTION: Despite the existence of over 30 anti-seizure medications (ASM), including 20 over the last 30 years, a third of patients with …
Placebo in epilepsy.
Goldenholz DM, Goldenholz SR. Goldenholz DM, et al. Int Rev Neurobiol. 2020;153:231-266. doi: 10.1016/bs.irn.2020.03.033. Epub 2020 Jun 9. Int Rev Neurobiol. 2020. PMID: 32563290 Review.
Placebos impact epilepsy in a number of ways. Through randomized clinical trials, explicit clinical use, and also through implicit clinical use, placebos play a role in epilepsy. This chapter will discuss the reasons placebo is used, the …
Placebos impact epilepsy in a number of ways. Through randomized clinical trials, explicit clinical use, and als …
Epilepsy biomarkers.
Engel J Jr, Pitkänen A, Loeb JA, Dudek FE, Bertram EH 3rd, Cole AJ, Moshé SL, Wiebe S, Jensen FE, Mody I, Nehlig A, Vezzani A. Engel J Jr, et al. Epilepsia. 2013 Aug;54 Suppl 4(0 4):61-9. doi: 10.1111/epi.12299. Epilepsia. 2013. PMID: 23909854 Free PMC article. Review.
Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the presence and severity of tissue …
Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity t …
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T; ILAE Subcommission on AED Guidelines. Glauser T, et al. Epilepsia. 2013 Mar;54(3):551-63. doi: 10.1111/epi.12074. Epub 2013 Jan 25. Epilepsia. 2013. PMID: 23350722 Free article. Review.
The purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untre …
The purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evide …
Cannabinoid therapy in epilepsy.
Billakota S, Devinsky O, Marsh E. Billakota S, et al. Curr Opin Neurol. 2019 Apr;32(2):220-226. doi: 10.1097/WCO.0000000000000660. Curr Opin Neurol. 2019. PMID: 30676535 Review.
PURPOSE OF REVIEW: To review the history, pharmacology, and clinical science of cannabidiol (CBD) in the treatment of epilepsy. ...SUMMARY: Identification of CBD, delta9-THC, and the endocannabinoid system in the mid-20th century has led to advancement of cannabis-b …
PURPOSE OF REVIEW: To review the history, pharmacology, and clinical science of cannabidiol (CBD) in the treatment of epilepsy …
Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic and clinical response to diagnostic intravenous antiseizure medication trials.
Leitinger M, Gaspard N, Hirsch LJ, Beniczky S, Kaplan PW, Husari K, Trinka E. Leitinger M, et al. Epilepsia. 2023 Sep;64(9):2351-2360. doi: 10.1111/epi.17694. Epub 2023 Jul 10. Epilepsia. 2023. PMID: 37350392 Free article.
OBJECTIVE: The Salzburg criteria for nonconvulsive status epilepticus (NCSE) and the American Clinical Neurophysiology Society (ACNS) Standardized Critical Care EEG Terminology 2021 include a diagnostic trial with intravenous (IV) antiseizure medications (ASMs) to a …
OBJECTIVE: The Salzburg criteria for nonconvulsive status epilepticus (NCSE) and the American Clinical Neurophysiology Society (ACNS) …
Cannabinoids for epilepsy.
Gloss D, Vickrey B. Gloss D, et al. Cochrane Database Syst Rev. 2014 Mar 5;2014(3):CD009270. doi: 10.1002/14651858.CD009270.pub3. Cochrane Database Syst Rev. 2014. PMID: 24595491 Free PMC article. Review.
It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. ...Secondary outcomes included responder rate at six months or more, objective quality of life data, an …
It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly a …
Lacosamide.
Doty P, Rudd GD, Stoehr T, Thomas D. Doty P, et al. Neurotherapeutics. 2007 Jan;4(1):145-8. doi: 10.1016/j.nurt.2006.10.002. Neurotherapeutics. 2007. PMID: 17199030 Free PMC article. Review.
The most frequently reported adverse events (> or =10% of lacosamide-treated patients) included dizziness, headache, and nausea. A double-blind, double-dummy randomized trial of intravenous lacosamide (30- and 60-minute infusion) as replacement for oral lacosamid …
The most frequently reported adverse events (> or =10% of lacosamide-treated patients) included dizziness, headache, and nausea. A double …
Cannabinoids for epilepsy.
Gloss D, Vickrey B. Gloss D, et al. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD009270. doi: 10.1002/14651858.CD009270.pub2. Cochrane Database Syst Rev. 2012. PMID: 22696383 Updated. Review.
It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. OBJECTIVES: To assess the efficacy of marijuana, or one of marijuana's constituents in the treatment of …
It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly a …
34,081 results
You have reached the last available page of results. Please see the User Guide for more information.